ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $102.14 Average Target Price from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received an average rating of “Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $102.1429.

A number of brokerages have weighed in on ANIP. HC Wainwright upped their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Barclays began coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 8th.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $80.39 on Friday. The firm has a market capitalization of $1.81 billion, a PE ratio of 49.32 and a beta of 0.48. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $99.50. The firm has a 50-day moving average price of $87.61 and a 200 day moving average price of $80.86.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same period in the previous year, the business earned $1.34 earnings per share. The company’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Patrick D. Walsh sold 8,643 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $86.88, for a total transaction of $750,903.84. Following the sale, the director directly owned 61,405 shares in the company, valued at $5,334,866.40. This represents a 12.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Chad Gassert sold 14,642 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the transaction, the senior vice president owned 158,584 shares of the company’s stock, valued at approximately $14,125,076.88. The trade was a 8.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 27,379 shares of company stock worth $2,411,321 over the last ninety days. 12.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in shares of ANI Pharmaceuticals by 9.1% in the third quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock worth $138,000 after acquiring an additional 126 shares during the last quarter. Illinois Municipal Retirement Fund increased its holdings in shares of ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock valued at $782,000 after purchasing an additional 145 shares in the last quarter. Amalgamated Bank increased its holdings in shares of ANI Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock valued at $464,000 after purchasing an additional 154 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after purchasing an additional 198 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its holdings in ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.